top of page
News
Jan 31, 2023
Jan 13, 2023
Jan 31, 2023
Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodies
Research indicates that NPTXR may have utility for treatment of gastro-intestinal cancers. Read more here: https://www.prnewswire.com/new...
Jan 31, 2023
Drug Discovery & Development
Ymmunobio get ownership rights to NPTXR antibodies. Read more here: https://www.drugdiscoverytrends.com/ymmunobio-gets-ownership-rights-t...
Jan 13, 2023
Fierce Biotech: Appointment of Michel Janicot
Michel Janicot will serve in the newly created position of chief development officer. https://www.fiercebiotech.com/biotech/chutes-ladder...
Jan 10, 2023
Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer
Ymmunobio adds to executive team. Read more here: https://www.biopharmadive.com/press-release/20230109-ymmunobio-appoints-dr-michel-janic...
bottom of page